Skip to main content

Prescription medicine

Fomepizole First approved as Antizol

Fomepizole (Antizol) is a prescription medicine with an FDA approval on record since 1997. FDA's NDC Directory lists it from 6 generic labelers.

  • Generic listed

Check it at the source: the fomepizole FDA label on DailyMed (effective December 19, 2024); the NDA 20696 record on Drugs@FDA; every fomepizole label on DailyMed.

Highlights of the record

FDA label of December 19, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage

Fomepizole is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see DOSAGE AND ADMINISTRATION ).

Forms and strengths

  • 1 g/ml
  • 1.5 g/1.5ml

Injection (solution); injection.

On the market

Earliest approval on file
December 4, 1997 Antizol, Par Pharm Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals
5 first December 14, 2007; 4 with a marketed status in Drugs@FDA
Labelers listed (NDC)
6 of which 6 under generic applications, 0 under brand applications, repackagers included
Last listed patent
June 30, 2027 Antizol injection; not a generic launch date

Supply and safety

Pharmacy cost (NADAC)
Not in the survey
Shortage (FDA)
No current entry
Recalls by its makers (FDA)
1 since 2015 0 Class I among all firms' recalls; latest March 9, 2015
FAERS reports
189 through July 30, 2026

What is fomepizole used for?

From the label: indications and usage

Fomepizole is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see DOSAGE AND ADMINISTRATION ).

FDA pharmacologic class: Antidote.

Source: FDA drug label (Fomepizole), Navinta LLC, effective December 19, 2024 (SPL set 6fed6052-f159-46d6-8be1-31e18a7ba918), via openFDA; the full label on DailyMed

Is there a generic for fomepizole (Antizol)?

The FDA approved the first generic fomepizole on December 14, 2007. 5 generic applications are approved; 4 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.

FDA's NDC Directory lists fomepizole from 6 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.

The Orange Book lists 1 patent for Antizol injection: the compound patent runs to June 30, 2027. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

  • 1997 earliest approval on file
  • 2007 first generic approved
  • 2027 last listed patent
  • red ticks recalls

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

Has fomepizole been recalled?

The FDA's Enforcement Report lists 1 recall naming fomepizole since 2015: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.

StartedClassCompanyReason
March 9, 2015Class IINavinta LLCLack of Assurance of Sterility. A recent FDA inspection reported GMP violations potentially impacting product quality and sterility.

Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026

What do FAERS reports show for fomepizole?

The FDA Adverse Event Reporting System holds 189 reports that list fomepizole among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 69 are coded as a death and 137 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

  • Drug Ineffective (a use or a product term, not a reaction)69
  • Toxicity To Various Agents50
  • Overdose (a use or a product term, not a reaction)37
  • Off Label Use (a use or a product term, not a reaction)33
  • Metabolic Acidosis23
  • Hypotension (named in the label)18
  • Intentional Overdose (a use or a product term, not a reaction)18
  • Hepatotoxicity17

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Other antidotes
the pharmacologic class, with prices and generics
Fomepizole side effects
the label's list beside FAERS reports
Check an interaction
what two or more labels say about each other